This is a reference to the two-phase solution being proposed by the co-chairmen of the so-called Minsk Group of the OSCE -- the Organisation for Security and Co-operation in Europe -- which is mediating a settlement.
Eli Lilly, for example, a major pharmaceutical company, invested an enormous amount in a drug as a potential solution, but had to terminate it in Phase 3 trials because the medication worsened the patient rather than improved the condition.
Most of these have been locked up by Dow, which developed its Insite metallocenes for solution-based polyethylene production, and by Exxon, which commercialised metallocenes for a gas-phase polyethylene process.